In addition, there are mutation-specific antibodies against exon 19-deleted or L858R-mutant EGFR, but given the multitude of immunohistochemical, DNA-, and RNA-based biomarkers, which have to be evaluated in a limited NSCLC tissue sample, we would abstain from the use of tissue slides for targeted detection of individual mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.